title: [Thrombocytopenia induced by lipopolysaccharide may be not related to coagulation and inflammatory response].
abstract: OBJECTIVE
  To explore the relationship between thrombocytopenia (TCP) induced by lipopolysaccharide (LPS) and coagulation or inflammatory response in mouse.
  
  
  METHODS
  Forty-eight C57BL/6 mice were divided into control group, low-dose, and high-dose LPS treatment groups by random number table method, and each group was subdivided into 4-hour and 24-hour subgroups randomly, with 8 mice in each subgroup. 0.5 mg/kg or 50 mg/kg LPS was injected intraperitoneally in low-dose or high-does group respectively, and equal amount of normal saline was injected in control group. Blood was collected from endocanthal vein at the specified time point, platelet count (PLT) was counted, and the levels of thrombin antithrombin complex (TAT), D-dimer, fibrinogen degradation product (FDP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were determined by enzyme linked immunosorbent assay (ELISA).
  
  
  RESULTS
  Compared with control group, PLT ( x 10(9)/L) at 4 hours and 24 hours in low-dose and high-dose LPS groups was significantly decreased (4 hours: 660.65 ± 180.48, 568.55 ± 117.99 vs. 1 199.13 ± 110.54; 24 hours: 505.63 ± 218.92, 256.33 ± 72.86 vs. 1 229.13 ± 1 189.37, all P < 0.05), and the changes were more obvious in high-dose LPS group compared with those of the low-dose LPS group (all P < 0.05). Factorial analysis showed that the changes in PLT were related with LPS dosage and time (F1 = 135.660, P = 0.000; F2 = 12.120, P2 = 0.001). It was also found that there was an interactive effect of the dose of LPS and time on PLT (F = 5.580, P = 0.007). Compared with control group, TAT, TNF-α, and IL-6 at 4 hours and 24 hours in low-dose and high-dose LPS groups were significantly decreased [TAT (ng/L) at 4 hours: 1.10 ± 0.59, 0.22 ± 0.13 vs. 3.47 ± 1.73; 24 hours: 1.18 ± 0.68, 0.39 ± 0.29 vs. 3.19 ± 1.27; TNF-α (nmol/L) at 4 hours: 87.35 ± 12.29, 93.70 ± 5.25 vs. 101.59 ± 10.96, 24 hours: 81.94 ± 8.26, 93.23 ± 4.71 vs. 102.84 ± 10.56; IL-6 (ng/L) at 4 hours: 81.78 ± 7.82, 78.59 ± 9.06 vs. 110.88 ± 9.66, 24 hours: 76.03 ± 9.85, 71.34 ± 3.69 vs. 110.88 ± 10.35, all P < 0.05]. TAT at 4 hours and 24 hours in high-dose LPS group was further decreased, and TNF-α at 24 hours was increased as compared with those of low-dose LPS group (all P < 0.05). TAT, TNF-α and IL-6 were influenced only by different dosage of LPS (TAT: F = 42.350, P = 0.000; TNF-α: F = 14.8 10, P = 0.000; IL-6: F = 81.910, P = 0.000), not time (TAT: F = 0.002, P = 0.967; TNF-α: F = 0.342, P = 0.562; IL-6: F = 2.973, P = 0.092). Changes in TAT was not found to be related with the dose of LPS and its time of action, or levels of TNF-α and IL-6 (TAT: F = 0.236, P = 0.791; TNF-α: F = 0.572, P = 0.569; IL-6: F = 0.774, P = 0.468). The dosage of LPS and time of admission showed no influence on D-dimer (F1 = 2.448, P = 0.099; F2 = 0.024; P2 = 0.877). The effect of different doses of LPS and time of administration showed no influence on FDP (F1 = 0.106, P = 0.900; F2 = 0.013, P2 = 0.908), and no interactive effects were found (D- dimer: F = 0.002, P = 0.998; FDP: F = 0.582, P = 0.563).
  
  
  CONCLUSIONS
  LPS can induce TCP in mouse, but this effect may not related to the activation of coagulation system and excessive inflammatory response.
authors.forename: Ji
authors.initials: J
authors.lastname: Xiang
authors.forename: Yao
authors.initials: Y
authors.lastname: Fangchao
authors.forename: Wang
authors.initials: W
authors.lastname: Bing
authors.forename: Wang
authors.initials: W
authors.lastname: Yongqiang
authors.forename: Cao
authors.initials: C
authors.lastname: Shuhua
authors.forename: Wang
authors.initials: W
authors.lastname: Yuliang
mesh_terms: D000818:Animals; D000990:Antithrombin III; D001777:Blood Coagulation; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D007249:Inflammation / Q000473:pathology*; D015850:Interleukin-6 / Q000097:blood; D008070:Lipopolysaccharides; D051379:Mice; D008810:Mice, Inbred C57BL; D010447:Peptide Hydrolases / Q000097:blood; D011897:Random Allocation; D013921:Thrombocytopenia / Q000139:chemically induced / Q000473:pathology*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D015850:Interleukin-6; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; D000990:Antithrombin III; D010447:Peptide Hydrolases